ライフサイエンスコーパス: pneumonitis

1 irl with fire-eater's pneumonia (hydrocarbon pneumonitis).

2 y oedema and one due to pleural effusion and pneumonitis).

3 , grade 2 hyperthyroidism, recurrent grade 4 pneumonitis).

4 mal hepatic function, hepatic cirrhosis, and pneumonitis).

5 b, and one treatment-related death occurred (pneumonitis).

6 8% (95% CI, 0.4%-1.2%) for grade 3 or higher pneumonitis.

7 .6%; P < .001) but not for grade 3 or higher pneumonitis.

8 rse events (AEs); 7% of patients (n = 4) had pneumonitis.

9 sensory neuropathy, and one case of grade 4 pneumonitis.

10 of the scurfy donor, including hepatitis and pneumonitis.

11 ilimumab 1 mg/kg died from treatment-related pneumonitis.

12 including one patient from bleomycin-induced pneumonitis.

13 are no biomarkers that can predict radiation pneumonitis.

14 ed and were attributed to treatment-emergent pneumonitis.

15 signaling and protect from bleomycin-induced pneumonitis.

16 PAR1 to ERK, and inhibits bleomycin-induced pneumonitis.

17 in the use of CT or PET to predict radiation pneumonitis.

18 of patients) occurred, each associated with pneumonitis.

19 TH17-mediated lung disease, hypersensitivity pneumonitis.

20 tive pulmonary disease, and hypersensitivity pneumonitis.

21 rectivirgula in a model of hypersensitivity pneumonitis.

22 nic rejection after IS withdrawal because of pneumonitis.

23 the treatment of a mouse model of autoimmune pneumonitis.

24 of fibrosis in experimental hypersensitivity pneumonitis.

25 One patient in each arm had fatal pneumonitis.

26 gen exposure known to cause hypersensitivity pneumonitis.

27 e of IL-17A in experimental hypersensitivity pneumonitis.

28 elated adverse events like neurotoxicity and pneumonitis.

29 tial pneumonia, and chronic hypersensitivity pneumonitis.

30 mortality in a CD8+ T cell-specific model of pneumonitis.

31 , consistent with more severe alveolitis and pneumonitis.

32 II BMT mice are only modestly protected from pneumonitis.

33 8% grade 3 esophagitis, and 7% grade 3 to 4 pneumonitis.

34 ly ill patients and can lead to pneumonia or pneumonitis.

35 kine in fibrotic disease and likely promotes pneumonitis.

36 ontrol microbial Ag-induced hypersensitivity pneumonitis.

37 mucositis; however, four patients developed pneumonitis.

38 odel of B. subtilis-induced hypersensitivity pneumonitis.

39 had grade 3 toxicities including one grade 3 pneumonitis.

40 rom SARS-CoV-infected aged mice that develop pneumonitis.

41 utation developed autoimmune myocarditis and pneumonitis.

42 There were no cases of radiation pneumonitis.

43 sed risk for death due to bladder cancer and pneumonitis.

44 One patient died due to ADV pneumonitis.

45 ents, including potentially life-threatening pneumonitis.

46 s, catheter-related infections, and possible pneumonitis.

47 cells and protect mice from fatal autoimmune pneumonitis.

48 umber of HLA mismatches, and cytomegalovirus pneumonitis.

49 ctions, acute rejection, and cytomegalovirus pneumonitis.

50 he gemcitabine plus berzosertib group due to pneumonitis.

51 ance in triaging research priorities for ICI-pneumonitis.

52 patient who received triplet therapy died of pneumonitis.

53 sis, beryllium disease, and hypersensitivity pneumonitis.

54 vent and two treatment-related deaths due to pneumonitis.

55 ration pneumonia or non-bacterial aspiration pneumonitis.

56 , albeit with a potential high risk of fatal pneumonitis.

57 d adequate organ function, and no history of pneumonitis.

58 ival in people with chronic hypersensitivity pneumonitis.

59 he 49 patients with non-bacterial aspiration pneumonitis.

60 occurred over time in patients who developed pneumonitis.

61 had higher rates of grade 2 or greater acute pneumonitis (1.2% vs. 0.2%, P=0.01) and lymphedema (8.4%

62 .6% vs 1.6%; P < .001) and grade 3 or higher pneumonitis (1.5% vs 0.2%; P = .001) in melanoma, with 1

63 .1% vs 1.6%; P = .002) and grade 3 or higher pneumonitis (1.8% vs 0.2%; P < .001) compared with melan

64 de 3-4 treatment-related adverse events were pneumonitis (10 [2%] of 550) and fatigue (5 [1%] of 550)

65 tively) and all-grade and grade 3 or greater pneumonitis (10.0% and 6.4%, respectively) but did not i

66 ncluded transient hypoxemia (19%), radiation pneumonitis (11%), and fatigue (4%).

67 fever (21%), hemorrhagic cystitis (12%), and pneumonitis (11%).

68 11%; P = .03]), while rates of grade 3 to 4 pneumonitis (12% vs 9%; P = .12) and esophagitis (23% vs

69 ctions and/or bacteremia (16%), and possible pneumonitis (18%).

70 cemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%).

71 acute respiratory distress syndrome (5.7%), pneumonitis (3.8%), and atrial fibrillation (2.9%).

72 daily group; p=0.85) and grade 3-4 radiation pneumonitis (4 [3%] of 254 vs 4 [2%] of 246; p=0.70).

73 CC was higher than in melanoma for all-grade pneumonitis (4.1% vs 1.6%; P < .001) but not for grade 3

74 Autoimmune events included pneumonitis (6 [13%]) and hypothyroidism (5 [10%]), most

75 e (15%), muscle weakness (6%), anxiety (6%), pneumonitis (6%), and rash (6%).

76 IMRT was associated with less >/= grade 3 pneumonitis (7.9% v 3.5%, P = .039) and a reduced risk i

77 ncluded liver function test elevation (14%), pneumonitis (9%), diarrhea (4%), nausea (4%), fatigue (4

78 xel included febrile neutropenia (10.9%) and pneumonitis (9.6%); 28.8% of patients were hospitalized

79 d a multifocal mononuclear cell interstitial pneumonitis, accompanied by multinucleated syncytial cel

80 Three deaths were attributed to treatment (pneumonitis, acute respiratory failure, and cardiovascul

81 pare the incidence of PD-1 inhibitor-related pneumonitis among different tumor types and therapeutic

82 withdrawal syndrome and sirolimus-associated pneumonitis and arthralgia.

83 RT was associated with lower rates of severe pneumonitis and cardiac doses in NRG Oncology clinical t

84 remia (n = 3), CMV syndrome (n = 1), and CMV pneumonitis and colitis (n = 1).

85 MV viremia (n=3), CMV syndrome (n=1) and CMV pneumonitis and colitis (n=1).

86 ibody defects, cytopenias, and T lymphocytic pneumonitis and colitis, with reduced peripheral blood m

87 athological findings, including interstitial pneumonitis and consolidation, is also remarkably reduce

88 e IPF compared with nonspecific interstitial pneumonitis and controls, which rose sharply during an a

89 in an enhanced immune-mediated interstitial pneumonitis and delayed clearance of SARS-CoV from the l

90 l signs of viral infection, mild to moderate pneumonitis and extra-pulmonary pathologies, and both ag

91 diotherapy is a mainstay for cancer therapy, pneumonitis and fibrosis constitute dose-limiting side e

92 ave also developed a mitigator for radiation pneumonitis and fibrosis that can be started as late as

93 ity can occur due to a combination of edema, pneumonitis and fibrosis.

94 of treatment-related adverse events (grade 4 pneumonitis and grade 4 thrombocytopenia) and subsequent

95 , beryllium sensitivity, or hypersensitivity pneumonitis and healthy subjects were analyzed for the p

96 tiple organ dysfunction syndrome, pneumonia, pneumonitis and hepatitis, respiratory failure, and sudd

97 th non-tuberculosis pulmonary hypersensitive pneumonitis and Mycobacterium avium infections.

98 V) viremia and two cases of CMV disease (one pneumonitis and one enteritis).

99 Incidence of all-grade and grade 3 or higher pneumonitis and pneumonitis-related deaths.

100 changes associated with infection, including pneumonitis and pulmonary consolidation.

101 ranscript in AECs enhanced radiation-induced pneumonitis and pulmonary fibrosis, and increased the ex

102 ula in this murine model of hypersensitivity pneumonitis and pulmonary fibrosis.

103 Patients with interstitial pneumonitis and pulmonary hemosiderosis were also more l

104 ry low-birth-weight (VLBW) infants can cause pneumonitis and sepsislike illness.

105 Using a nonlymphopenic model of autoimmune pneumonitis and T(Reg) with known Ag specificity, in thi

106 ry fibrosis in experimental hypersensitivity pneumonitis and to determine the main inflammatory cell

107 rring diagnosis of desquamative interstitial pneumonitis and who were older than 10 years at the time

108 The impact on progression to pneumonitis and/or mortality of treating parainfluenza v

109 re consistent with subacute hypersensitivity pneumonitis (and IgG positive).

110 p (one each of interstitial lung disease and pneumonitis) and three in the chemotherapy group (one ea

111 ab plus tremelimumab group (septic shock and pneumonitis), and one (<1%) patient in the chemotherapy

112 gnised expertise in chronic hypersensitivity pneumonitis, and further research and studies at other c

113 iremia and hepatitis, pneumocystis jirovecii pneumonitis, and generalized lymphadenopathy.

114 biopsy shows findings of usual interstitial pneumonitis, and he has no identifiable cause for pulmon

115 ntly diagnosed with chronic hypersensitivity pneumonitis, and most of these cases were attributed to

116 ated to treatment included two patients with pneumonitis, and one each with constitutional symptoms,

117 ing two with adrenal insufficiency, two with pneumonitis, and one with nephritis.

118 ointestinal ulcers, cholecystitis, radiation pneumonitis, and radioembolization-induced liver disease

119 Pneumonitis (any grade) was detected in 22 (8%) patients

120 The risk of pneumonitis appeared related to the ILV treated.

121 Patients with hypersensitivity pneumonitis are at risk of developing pulmonary fibrosis

122 r latent viral load, BMT mice develop severe pneumonitis associated with reduced oxygen saturation, f

123 There were four cases of pneumonitis at 4, 4, 7, and 9 months after treatment.

124 cterial aspiration pneumonia from aspiration pneumonitis based on quantitative bronchoalveolar lavage

125 ed as a result of autoimmune myocarditis and pneumonitis before developing renal disease or the syste

126 -forming units (IFU) of C. trachomatis mouse pneumonitis biovar (MoPn) and were euthanized at 10 days

127 hocytic alveolitis, lymphocytic interstitial pneumonitis, bronchoalveolar obliterans organizing pneum

128 ronavirus (SARS-CoV), primarily present with pneumonitis but may also develop hepatic, gastrointestin

129 atients had no evidence for hypersensitivity pneumonitis, but 70% of cases had a personal or family h

130 rine models of experimental hypersensitivity pneumonitis, but its role in the development of pulmonar

131 gnificantly protected from the hepatitis and pneumonitis, but not the dermatitis, induced by adoptive

132 fibrosis (IPF) and chronic hypersensitivity pneumonitis can be indistinguishable; the need to elimin

133 There were four pneumonitis cases (three grade 2 and one grade 3).

134 role in the development of hypersensitivity pneumonitis caused by microbial Ags and that inhibition

135 of the current knowledge on hypersensitivity pneumonitis caused by the occupational environment and t

136 of visual assessment to recognize radiation pneumonitis, changes in lung configuration, and patterns

137 urrent diagnosis of chronic hypersensitivity pneumonitis (cHP) involves considering a combination of

138 of life of a large chronic hypersensitivity pneumonitis (CHP) patient sample.

139 Checkpoint inhibitor pneumonitis (CIP) is a highly morbid complication of imm

140 bined UCSF and UTSW chronic hypersensitivity pneumonitis cohort, we saw associations between extent o

141 there were radiologic manifestations such as pneumonitis, colitis, hypophysitis, thyroiditis, or myoc

142 diologic presentation, and management of ICI-pneumonitis.Conclusions: Gaps in knowledge of the basic

143 ge of the basic biological mechanisms of ICI-pneumonitis, coupled with a precipitous increase in the

144 limited the rates of clinically significant pneumonitis, dose-limiting toxicity occurred and was dom

145 infections and occupational hypersensitivity pneumonitis due to metalworking fluid (MWF) exposures.

146 adverse effects, such as fibro-interstitial pneumonitis due to the acquisition of activated myofibro

147 The overall incidence of pneumonitis during PD-1 inhibitor monotherapy was 2.7% (

148 thought to have died from grade 5 radiation pneumonitis during the study; however, this adverse even

149 e found in incidence of acute skin reaction, pneumonitis, dyspnea, cough, dysphagia, or neutropenia.

150 rhoea, decreased appetite, hyponatremia, and pneumonitis (each in two [1%]) in those given pembrolizu

151 ell-characterized murine models of radiation pneumonitis/fibrosis to compare and contrast differentia

152 The risk of pneumonitis for the two cohorts combined was: 17% (four

153 95% CI: 1.38, 6.34; P for trend = 0.02) and pneumonitis (for >3.12 ppm-year vs. unexposed, HR = 4.73

154 luding: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]).

155 ia (five [10%] and two [10%], respectively), pneumonitis (four [8%] and none, respectively), oedema (

156 terstitial pneumonia, 16 as hypersensitivity pneumonitis, four as sarcoidosis, four as respiratory br

157 ne toxic death (66 Gy) and 1 case of grade 4 pneumonitis (>66 Gy) were reported.

158 and 11 years) with desquamative interstitial pneumonitis had ABCA3 mutations identified on both allel

159 The prevalence of lymphocytic interstitial pneumonitis had also dropped significantly following int

160 he 20 patients with chronic hypersensitivity pneumonitis had histopathological features on surgical l

161 ressive agents, had no active non-infectious pneumonitis, had no uncontrolled thyroid dysfunction or

162 h, colitis, hepatitis, endocrinopathies, and pneumonitis have been established.

163 fects of gender on rates of hypersensitivity pneumonitis have been shown.

164 duce IL-17A in experimental hypersensitivity pneumonitis have not yet been identified.

165 Hypersensitivity pneumonitis (HP) develops after inhalation of many diffe

166 Human cases of hypersensitivity pneumonitis (HP) have been reported among machinists for

167 Hypersensitivity pneumonitis (HP) is a complex syndrome caused by the inh

168 Hypersensitivity pneumonitis (HP) is a complex syndrome resulting from re

169 Hypersensitivity pneumonitis (HP) is a T(H)1 lymphocyte-biased fibrosing

170 Hypersensitivity pneumonitis (HP) is an inflammatory lung disease charact

171 Hypersensitivity pneumonitis (HP) is an inflammatory lung disease that de

172 Identifying early stages of hypersensitivity pneumonitis (HP) is hampered by variable presentation, h

173 re in patients with chronic hypersensitivity pneumonitis (HP) the computed tomographic (CT) imaging f

174 Hypersensitivity pneumonitis (HP), an inflammatory lung disease, develops

175 addresses the diagnosis of hypersensitivity pneumonitis (HP).

176 , 1.51-5.83]; P = .002), and cytomegalovirus pneumonitis (HR, 3.76 [95% CI, 1.23-11.49]; P = .02) wer

177 ns, fatigue, thrombocytopenia, noninfectious pneumonitis, hyperglycemia, and rash.

178 luded esophagitis in 14 v nine patients, and pneumonitis in 0 v 6 patients for HART and qdRT, respect

179 rminated early because of treatment-emergent pneumonitis in 18% of patients (severe in 11 of 12 cases

180 Final diagnosis: hypersensitivity pneumonitis in 47.3% (n = 513; exposure, 48.1% air coole

181 induce arthritis, ileitis, and interstitial pneumonitis in BALB/c ZAP70 (W163C)-mutant (SKG) mice vi

182 ariable analyses demonstrated higher odds of pneumonitis in NSCLC for all-grade (odds ratio [OR], 1.4

183 ls, but not B cells, prevented hepatitis and pneumonitis in RAG(-/-) recipients of scurfy lymphocytes

184 15 Gy of x-rays to the thorax causes severe pneumonitis in rats by 6-8 wk.

185 We therefore examined the risk of pneumonitis in relation to lung dose-volume parameters.

186 n that excessive T cell activity can mediate pneumonitis in the setting of influenza infection, and d

187 Early prediction of radiation pneumonitis in time to initiate mitigation will benefit

188 nia, elevated lipase, hypophosphataemia, and pneumonitis in two (1%) patients each.

189 mouse model of experimental hypersensitivity pneumonitis in which IL-17A was inhibited or neutrophils

190 Mice died from an acute lymphocytic pneumonitis in which T and NK cells dominate a severe in

191 +) bone marrow cells induced myocarditis and pneumonitis in WT;MRL(+/+) mice, despite a dramatic up-r

192 plantation patients who develop interstitial pneumonitis include idiopathic pneumonia syndrome and br

193 red in 15 (5%) of 310 treated patients, with pneumonitis, increased aspartate aminotransferase, incre

194 of bleomycin-treated WT mice display: severe pneumonitis; increased generation of superoxide; vascula

195 ur knowledge, a novel model of proliferative pneumonitis involving macrophages and epithelial cells a

196 HIV-1-induced interstitial pneumonitis (IP) is a serious complication of HIV-1 infe

197 rom patients with RA-associated interstitial pneumonitis (IP) were examined by immunohistochemistry.

198 rammed cell death 1 (PD-1) inhibitor-related pneumonitis is a rare but clinically serious and potenti

199 Bleomycin-induced pneumonitis is an acute rather than late effect of treat

200 Hypersensitivity pneumonitis is an environmental lung disease characteriz

201 Hypersensitivity pneumonitis is an interstitial lung disease that results

202 Chronic hypersensitivity pneumonitis is characterized by pulmonary inflammation a

203 The diagnosis of ICI-pneumonitis is increasing; however, the biological mecha

204 greement for a diagnosis of hypersensitivity pneumonitis is low, highlighting an urgent need for stan

205 Radiation pneumonitis is reported in 5% to 15% of lung cancer pati

206 BLM-induced pneumonitis is the most feared, dose-limiting side effec

207 [0.37-0.49]); and fair for hypersensitivity pneumonitis (kappaw=0.29 [0.24-0.40]).

208 Other manifestations include eosinophilic pneumonitis, localized myositis, folliculitis, erythema

209 ars]), and 192 with chronic hypersensitivity pneumonitis (men, 76; women, 116; median age, 66 years [

210 d propose methods for future research on ICI-pneumonitis.Methods: A multidisciplinary group of intern

211 ding frames (ORFs) from C. trachomatis mouse pneumonitis (MoPn) genomic and plasmid DNA and tested it

212 es (MAbs) to the Chlamydia trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP) w

213 eparation of the Chlamydia trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP),

214 re inflammatory processes including colitis, pneumonitis, myocarditis, and shock.

215 aths (5%) occurred on therapy as a result of pneumonitis (n = 1), stroke (n =1), and heart failure (n

216 Manifestations included pneumonitis (n = 7), myocarditis (n = 5), brain abscesse

217 , syncope (n=1 [2%]), cellulitis (n=1 [2%]), pneumonitis (n=1 [2%]), headache (n=1 [2%]), lung infect

218 ort, and grade 3 colitis (n=1 [6%]), grade 3 pneumonitis (n=1 [6%]), grade 3 fatigue (n=1 [6%]), grad

219 ccurred in six (14%) of 42 patients and were pneumonitis (n=2), acute kidney injury, colitis, hypokal

220 ous adverse events were dyspnoea (n=3 [5%]), pneumonitis (n=3 [5%]), pericardial effusion (n=2 [3%]),

221 equent diagnosis of chronic hypersensitivity pneumonitis: nine patients had positive bronchial challe

222 r [7%]), diarrhoea (five [10%] vs one [2%]), pneumonitis (none vs five [9%]), stomatitis (none vs fiv

223 monary fibrosis (PAF, 26%); hypersensitivity pneumonitis (occupational burden, 19%); other granulomat

224 Pulmonary infections and pneumonitis occur frequently after hematopoietic stem ce

225 organizing pneumonia (BOOP) and interstitial pneumonitis occurred at 4 to 6 weeks, and 6 to 12 weeks,

226 Acute grade 2 pneumonitis occurred in 1 (2%) patient.

227 Late grades 2 and 3 pneumonitis occurred in 10 (16%) and 8 (12%), respective

228 Symptomatic pneumonitis occurred in one patient (2.6%).

229 Grade 5 treatment-related pneumonitis occurred in one patient each in the NIVO3 an

230 related to either drug, and one death due to pneumonitis occurred in the erlotinib plus cabozantinib

231 One dose-limiting toxic effect (death from pneumonitis) occurred at the highest administered dose (

232 s in the everolimus group, of whom eight had pneumonitis of grade 3 severity.

233 Occupational hypersensitivity pneumonitis (OHP) is an immunologic lung disease resulti

234 tigue (one patient given 30 mg/day), grade 3 pneumonitis (one given 60 mg/day), and grade 4 thrombocy

235 d were diarrhoea, diabetic ketoacidosis, and pneumonitis (one patient each) in the nivolumab group, a

236 rterial injury (one), neutropenia (one), and pneumonitis (one).

237 ts of patients with chronic hypersensitivity pneumonitis, one from the University of California San F

238 There was one grade 5 adverse event (AE) of pneumonitis, one grade 4 thrombosis, and nine other grad

239 sy that was consistent with hypersensitivity pneumonitis; one was IgG positive plus had greater than

240 Drug-related interstitial pneumonitis or cardiac dysfunction associated with other

241 t of severe clinical manifestations, such as pneumonitis or eye complications; (ii) patients with a p

242 Dose-limiting pneumonitis or myelosuppression was observed in three of

243 A definitive diagnosis of aspiration pneumonitis or pneumonia is challenging to make.

244 .60-5.08; P < .001) and in RCC for all-grade pneumonitis (OR, 1.59; 95% CI, 1.32-1.92; P < .001) comp

245 , 1.08-1.89; P = .005) and grade 3 or higher pneumonitis (OR, 2.85; 95% CI, 1.60-5.08; P < .001) and

246 , 1.69-2.50; P < .001) and grade 3 or higher pneumonitis (OR, 2.86; 95% CI, 1.79- 4.35; P < .001).

247 ng corrected QT interval (QTc) prolongation, pneumonitis, or neuropathic pain.

248 orted 20 cases of interstitial lung disease, pneumonitis, or organising pneumonia, including one grad

249 ses; interstitial fibrosis; hypersensitivity pneumonitis; other noninfectious granulomatous lung dise

250 e of 192 (4.7%) had chronic hypersensitivity pneumonitis (P < .001), and 27 of 244 (11.1%) had nonspe

251 ically latent period, the intermediate acute pneumonitis phase and the later fibrotic stage.

252 dnTGFbetaRII are largely protected from the pneumonitis phenotype, whereas mice with CD11c-dnTGFbeta

253 infiltrates, pulmonary infection, aspiration pneumonitis, pleural effusion, atelectasis, cardiopulmon

254 A CT appearance resembling hypersensitivity pneumonitis, reflecting the exquisitely bronchiolocentri

255 (1.5% vs 0.2%; P = .001) in melanoma, with 1 pneumonitis-related death during combination therapy.

256 Four pneumonitis-related deaths were observed in patients wit

257 -grade and grade 3 or higher pneumonitis and pneumonitis-related deaths.

258 refine research questions pertaining to ICI-pneumonitis.Results: This statement identifies gaps in k

259 20 was associated with increased >/= grade 3 pneumonitis risk on multivariable analysis ( P = .026).

260 r associations with chronic hypersensitivity pneumonitis risk, survival, and clinical, radiographic,

261 the incidence of grade 3 or higher radiation pneumonitis (RP) or any grade 4 toxicity within 3 months

262 he incidence of grade 3 or greater radiation pneumonitis (RP).

263 ern consistent with chronic hypersensitivity pneumonitis); seven were IgG positive plus had histopath

264 nosed as having summer-type hypersensitivity pneumonitis (SHP).

265 diagnosed with summer-type hypersensitivity pneumonitis (SHP).

266 cute lung injury (ALI) during both the acute pneumonitis stage and progression into the chronic fibro

267 ritoneal macrophages infected with the mouse pneumonitis strain of C. trachomatis.

268 al in patients with chronic hypersensitivity pneumonitis suggest shared pathobiology with IPF, and mi

269 cterium avium complex, lymphoid interstitial pneumonitis, systemic fungal infection, cytomegalovirus

270 50 in patients with chronic hypersensitivity pneumonitis than in healthy controls (24.4% in UCSF and

271 In a mouse model of hypersensitivity pneumonitis that progresses to lung fibrosis upon repeat

272 l researchers reviewed available data on ICI-pneumonitis to develop and refine research questions per

273 Consequences range from subclinical pneumonitis to respiratory failure, with fibrosis develo

274 genetically identical mice varied from mild pneumonitis to severe acute lung injury with extensive p

275 [3%]); in group B, diarrhoea (two [3%]) and pneumonitis (two [3%]); and in group C, neutropenia (fou

276 creased lipase (three [8%] and no patients), pneumonitis (two [5%] and one [3%] patients), adrenal in

277 Delayed-onset CMV pneumonitis was associated with inpatient death longer t

278 Minimal pneumonitis was associated with the lung infection, but

279 nce: The incidence of PD-1 inhibitor-related pneumonitis was higher in NSCLC and RCC and during combi

280 These results suggest that delayed-onset CMV pneumonitis was independently associated with an increas

281 Hypersensitivity pneumonitis was induced in C57BL/6 wild-type or recombin

282 Pneumonitis was more frequent during combination therapy

283 No grade 3 pneumonitis was observed and an MTD for acute toxicity w

284 No clinically significant noninfectious pneumonitis was observed.

285 ptomatic cardiotoxicity, and no interstitial pneumonitis was reported.

286 By day 7, histopathologic evidence of pneumonitis was seen in the lungs when viral clearance o

287 Hypersensitivity pneumonitis was the most common new-onset ILD in India,

288 Pneumonitis was the most common radiologic manifestation

289 found that the severity of hypersensitivity pneumonitis was unaffected by vancomycin, but increased

290 ith ALI and lungs from mice with LPS-induced pneumonitis, we found that pulmonary SDF-1 expression in

291 established murine model of hypersensitivity pneumonitis, we repeatedly exposed C57BL/6 mice to Sacch

292 ocytic bronchiolitis, BOOP, and interstitial pneumonitis were directly associated with the developmen

293 s of veno-occlusive disease and interstitial pneumonitis were high at 20%.

294 interstitial pneumonia and hypersensitivity pneumonitis, were reclassified as IPF.

295 (IPF) or chronic (fibrotic) hypersensitivity pneumonitis, which suggests these disorders share risk f

296 Three patients died of pneumonitis while in the study.

297 Incidence of pneumonitis with temsirolimus/bevacizumab was 4.8%, most

298 g to patients' stratified risk for radiation pneumonitis with total RT doses ranging from 57 to 85.5

299 zed by viremia in the presence or absence of pneumonitis, with viral loads higher in the lung airways

300 the patient developed persistent SARS-CoV-2 pneumonitis, without progressing to multi-organ involvem